Clinical Trial Update: A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) [Phase 3]

View source ↗

Summary

Phase 3 study of bomedemstat (MK-3543-017) sponsored by Merck is currently recruiting to evaluate safety and efficacy in essential thrombocythemia and myelofibr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Bomedemstat (bomedemstat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Thrombocythemia, Essential, Primary Myelofibrosis | Phase 3 | Status: RECRUITING